Denali shares soar on potential $2.4 billion Parkinson's, Alzheimer's deal with Biogen
August 06, 2020 at 17:36 PM EDT
The deal includes a $560 million upfront payment and $465 million equity stake in the South San Francisco-based trailblazer in experimental neurodegenerative disease drugs.